Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels.

John Lindsay

Research output: Contribution to journalArticle

16 Citations (Scopus)
Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalPituitary
Volume7(3)
Issue number3
DOIs
Publication statusPublished - Oct 2004

ASJC Scopus subject areas

  • Endocrinology

Cite this